XBI ETF: What Is It? A Complete Guide to Returns, Expense Ratio, Holdings, and Alternative ETFs
SPDR S&P Biotech ETF (ticker XBI) tracks the US biotech industry on a modified equal-weight basis, which gives it large exposure to small-cap drug developers. The key selection criteria are how its structure differs from the market-cap-weighted IBB and from XLV, which invests across healthcare, along with dividends and outlook.
SubscribeWhat Is the SPDR S&P Biotech ETF?
This is a US biotech sector ETF that tracks the S&P Biotechnology Select Industry Index. Its core concept is a modified equal-weight method rather than market-cap weighting, which narrows the weight gap between holdings.
It suits growth-oriented investors who want broad exposure to the biotech industry, especially to the movements of small drug developers.
It is a passively managed (index-tracking) ETF run by State Street.
How Does the SPDR S&P Biotech ETF Invest?
| Item | Details |
|---|---|
| Tracked index | S&P Biotechnology Select Industry Index |
| Management style | Passive (index tracking) |
| Weighting method | Modified equal weight |
| Rebalancing frequency | Quarterly |
| Dividend frequency | Quarterly dividend |
| Expense ratio | 0.35% |
The fund holds the index constituents on a modified equal-weight basis to track the performance of the US biotech industry as a whole. Unlike market-cap-weighted ETFs, it has less concentration in large caps, so the share price movements of small and mid-sized drug developers are reflected relatively strongly in performance, and weights are readjusted through quarterly rebalancing.
- A modified equal-weight structure with less large-cap concentration
- Broad industry exposure that extends to small drug developers
SPDR S&P Biotech ETF Size and Costs (AUM and Management Fee)
Assets under management (AUM) stand at $10.6B, and the expense ratio is 0.35% per year.
Compared with the market-cap-weighted IBB, it has larger small-cap exposure and tends to be more sensitive to the volatility of individual stocks.
SPDR S&P Biotech ETF Performance and Trends
1-Year Price Performance
Dividend & Yield
52-Week Price RangeThe biotech sector reacts sensitively to clinical trial results, merger and acquisition expectations, and the interest rate environment, and because of the equal-weight structure, volatility tends to be high as small caps move. Short-term swings tend to be wide.
It is a sector where fund flows fluctuate sharply with interest rates and risk appetite. Money tends to flow in when clinical momentum or M&A expectations revive, and it tends to leave relatively quickly in risk-off phases.
SPDR S&P Biotech ETF Pros and Cons
Its strengths are broad biotech industry exposure and the equal-weight structure, while its weakness is the high volatility that comes from its small-cap weighting.
💪 Key Strengths
⚠️ Points to Watch
SPDR S&P Biotech ETF Alternative ETFs and Related Products
XLV, VHT, IYH, and FHLC, shown in the table, are broader ETFs that invest across the healthcare sector including biotech, and their volatility is relatively lower. A direct substitute targeting the same biotech industry is the market-cap-weighted IBB, which has a larger weighting in large caps. To focus on genomics and drug innovation, you can consider ARKG, for leveraged exposure LABU (3x), and if you need a bet in the opposite direction, LABD (inverse).
Peer Comparison ETFs| Ticker | Name | Price | Change | AUM | Total Expense Ratio | Dividend Yield | 1Y |
|---|---|---|---|---|---|---|---|
 XLV | State Street Health Care Select Sector SPDR ETF | $189.66 | +3.1% | $49.1B | 0.08% | 1.34% | +30.7% |
 VHT | Vanguard Health Care ETF | $351.23 | +3.1% | $20.7B | 0.09% | 1.31% | +29.7% |
 IYH | iShares U.S. Healthcare ETF | $79.85 | +3.3% | $4.7B | 0.37% | 1% | +30.9% |
 FHLC | Fidelity MSCI Health Care Index ETF | $90.77 | +3.1% | $3.9B | 0.08% | 1.12% | +30.0% |
 IHI | iShares U.S. Medical Devices ETF | $60.22 | +6.7% | $3.9B | 0.37% | 0.44% | -1.3% |
Top Holdings| Ticker | Name | Weight | Price | Change | Market Cap | P/E | Dividend Yield |
|---|---|---|---|---|---|---|---|
 OABI | OmniAb Inc | - | $5.18 | +0.6% | $755.6M | - | - |
 MYMK | State Street My2031 Municipal Bond ETF | 0.14% | $24.69 | +0.2% | $0.0M | - | 2.6% |
 ALKS | Alkermes plc | 0.01% | $45.89 | +0.4% | $7.7B | - | - |
| MRNA | Moderna Inc | 0.01% | $258.12 | +13.0% | $103.1B | - | - |
SPDR S&P Biotech ETF Investor Checkpoints
These are the points to review before investing in XBI. Because it is a biotech sector ETF, it is wise to check in advance the expense ratio, the high volatility that comes from the equal-weight structure, and the currency exposure of Korean-won investors before buying.
| Checkpoint | What to Check | Current Status |
|---|---|---|
| 💵 Expense ratio | Check the cumulative impact over a long holding period | Annual fee applies |
| 📊 Weighting method | Check small-cap exposure resulting from equal weighting | Modified equal weight |
| ⚡ Volatility | Whether you can tolerate clinical and event risk | On the high side |
| 💱 Exchange rate | Impact on returns converted to won | No currency hedge |
Short-term volatility is large because of the small-cap weighting and single-sector concentration. A failed clinical trial or a change in the regulatory environment can hit the whole sector at once, so losses can be large.
It is a suitable choice for investors who want to place a broad bet on the biotech industry, especially on small drug stocks. If you want the stability of a large-cap focus, IBB is an alternative, and if you want diversification across healthcare, XLV and VHT are alternatives.
SubscribeDisclaimer: This content is for informational purposes only and does not constitute investment advice. All investment responsibility lies with the investor.
This article reflects information as of June 21, 2026.
Today's 5 AI picks, all free